REAL-WORLD COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN SYMPTOMATIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PORTUGAL

被引：0
|
作者：
Afonso-Silva, M. [1 ]
Laires, P. A. [1 ]
机构：
[1] Prod Farmaceut SA, Novartis Farma, Porto Salvo, Portugal
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV24
引用
收藏
页码：S545 / S545
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina
    Giorgi, Mariano A.
    Boissonnet, Carlos P.
    Luque, Paula Soledad
    Piastrella, Jimena
    Porley, Carlos
    Ditata, Fernanda
    Volman, Sergio
    [J]. HEALTH ECONOMICS REVIEW, 2023, 13 (01)
  • [22] Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction
    Gaziano, Thomas A.
    Fonarow, Gregg C.
    Claggett, Brian
    Chan, Wing W.
    Deschaseaux-Voinet, Celine
    Turner, Stuart J.
    Rouleau, Jean L.
    Zile, Michael R.
    McMurray, John J. V.
    Solomon, Scott D.
    [J]. JAMA CARDIOLOGY, 2016, 1 (06) : 666 - 672
  • [23] Comparative Cost-Effectiveness of Sacubitril-Valsartan, Dapagliflozin, and Empagliflozin in Heart Failure With Reduced Ejection Fraction
    Parikh, Neil U.
    Dixit, Neal
    Ziaeian, Boback
    Fonarow, Gregg C.
    [J]. CIRCULATION, 2022, 146
  • [24] Reply: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction
    Liang, Lin
    Wu, David Bin-Chia
    Aziz, Mohamed Ismail Abdul
    Wong, Raymond
    Sim, David
    Leong, Kui Toh Gerard
    Wei, Yong Quek
    Tan, Doreen
    Ng, Kwong
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (12) : 1148 - 1149
  • [25] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN HEART FAILURE WITH REDUCED EJECTION FRACTION PATIENTS IN INDIAN HEALTHCARE SETTING
    Gokhale, S.
    Partha, G.
    Proudfoot, C.
    Anand, S.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S115 - S115
  • [26] Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context
    D'Angiolella, Lucia S.
    Cortesi, Paolo A.
    Pitotti, Claudia
    Ritrovato, Daniela
    Mantovani, Lorenzo G.
    Senni, Michele
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 (11) : 1551 - 1553
  • [27] PHARMACOUTILIZATION AND ADHERENCE TO SACUBITRIL/VALSARTAN IN REAL-WORLD: THE REAL.IT STUDY IN HEART FAILURE WITH REDUCED EJECTION FRACTION
    Iacoviello, M.
    Di Gesaro, G.
    Sarullo, F.
    Miani, D.
    Driussi, M.
    Correale, M.
    Bilato, C.
    Passantino, A.
    Carluccio, E.
    Villani, A.
    Esposti, L. Degli
    D'Agostino, C.
    Peruzzi, E.
    Poli, S.
    Di Lenarda, A.
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2023, 25
  • [28] Real world experience of sacubitril and valsartan in patients with heart failure with reduced ejection fraction
    Ganesananthan, S.
    Shah, N.
    Shah, P.
    Phillips, J.
    Elsayed, H.
    Yousef, Z.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 222 - 222
  • [29] THE COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN FOR THE TREATMENT OF CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN ALTERNATIVE AGE GROUPS
    Hancock, E.
    Trueman, D.
    Alexopoulos, S. T.
    Gielen, V
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A655 - A655
  • [30] Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction
    Gaziano, Thomas A.
    Fonarow, Gregg C.
    Velazquez, Eric J.
    Morrow, David A.
    Braunwald, Eugene
    Solomon, Scott D.
    [J]. JAMA CARDIOLOGY, 2020, 5 (11) : 1236 - 1244
12345